Difference between revisions of "Cetuximab (Erbitux)"
m |
|||
| Line 24: | Line 24: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | |||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:EGFR inhibitors]] | [[Category:EGFR inhibitors]] | ||
| + | |||
[[Category:Basal cell and squamous cell skin cancer medications]] | [[Category:Basal cell and squamous cell skin cancer medications]] | ||
[[Category:Colon cancer medications]] | [[Category:Colon cancer medications]] | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Head and neck cancer medications]] | ||
Revision as of 16:55, 5 September 2014
Also known as C225.
General information
Class/mechanism: EGFR antagonist; monoclonal antibody that binds to the EGFR/HER1/c-ErbB-1 receptor tyrosine kinase, competitively inhibiting binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha. This results in inhibition of cell growth, induction of apoptosis, decreased matrix metalloproteinase, and decreased vascular endothelial growth factor production.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cetuximab (Erbitux) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 8 of the package insert[1]
- Cetuximab (Erbitux) patient drug information (UpToDate)[5]